



ELSEVIER



Systems metabolomics: from metabolomic snapshots to design principles

Chiara Damiani^{1,2}, Daniela Gaglio^{2,3}, Elena Sacco^{1,2},
Lilia Alberghina^{1,2} and Marco Vanoni^{1,2}

Metabolomics is a rapidly expanding technology that finds increasing application in a variety of fields, from metabolic disorders to cancer, from nutrition and wellness to design and optimization of cell factories. The integration of metabolic snapshots with metabolic fluxes, physiological readouts, metabolic models, and knowledge-informed Artificial Intelligence tools, is required to obtain a system-level understanding of metabolism. The emerging power of multi-omic approaches and the development of integrated experimental and computational tools, able to dissect metabolic features at cellular and subcellular resolution, provide unprecedented opportunities for understanding design principles of metabolic (dis)regulation and for the development of precision therapies in multifactorial diseases, such as cancer and neurodegenerative diseases.

Addresses

¹ Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy

² ISBE.IT, SYSBIO Centre of Systems Biology, Piazza della Scienza 2, Milan 20126, Italy

³ Institute of Molecular Bioimaging and Physiology (IBFM), National Research Council (CNR), Segrate, Milan, Italy

Corresponding author: Vanoni, Marco (marco.vanoni@unimib.it)

Current Opinion in Biotechnology 2020, 63:190–199

This review comes from a themed issue on **Systems biology**

Edited by **Marco Vanoni** and **Pasquale Palumbo**

<https://doi.org/10.1016/j.copbio.2020.02.013>

0958-1669/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The last decade has witnessed an increasing technical capacity to collect different omic data, including transcriptomics, proteomics, phosphoproteomics, and metabolomics. Measurement of metabolite concentrations is the more straightforward and direct approach to characterize the metabolic state of cells, tissues, and biological fluids. Recent advances in analytical techniques provide now high sensitivity and specificity. Metabolic flux analysis, in which atoms derived from stable isotope-labeled substrates are detected as they label downstream

metabolic products, allows robust quantification of fluxes along biochemical pathways and can provide pathway-specific information more directly [1]. Changes in metabolic fluxes directly impact on epigenetic regulation and enzyme activities, affecting cell functions, which emerge from the network of informational and metabolite fluxes taking place in each given cell. Detailed workflows that allow quantification of metabolic rewiring in mammalian cell cultures have been recently provided ([2] and references therein).

Biological interpretation of these profiles and unambiguous identification of the affected biochemical pathways present a non-trivial task. Metabolism integrates information deriving from genetic, epigenetic, and environmental signals allowing to associate each physio-pathological condition to a specific metabolic fingerprinting [3]. We refer to the integrated use of complementary experimental and computational analyses in the study of metabolism as “systems metabolomics. This multi-layered approach allows to extract information from metabolomics and other metabolism-related data – such as transcriptomics and (phospho) proteomics – structuring it into knowledge. In the following, we review some recent advancements in systems metabolomics, outlining its use in precision medicine and wellness.


Understanding and exploiting metabolism: systems metabolomics

In recent years metabolomics has been applied successfully in multiple areas, from the discovery of novel mechanisms and new biomarkers to food and nutrition, from characterization and engineering of cell factories to the health and clinical field (Figure 1) [4–7,8^{••},9].

Metabolome and fluxome data are essential to understand the metabolic status of the producer strain during fermentation and identify engineering targets to enhance its performance further. Accordingly, emerging and successful strategies for developing industrial microbial strains, that is, cell factories capable of overproducing bioproducts, are based on system-wide metabolic engineering and optimization and require metabolomics analysis and genome-scale computational simulation [10,11].

In nutrition and wellness, complex metabolomics data from biological samples, such as saliva, blood, urine, and cerebrospinal fluid, are being used to discover novel biomarkers of dietary intake, host-environment interaction,

Figure 1



The central role of systems metabolomics in different fields.

acute and chronic physical activity, stress, and other extrinsic factors affecting human health and disease [12–14]. Metabo-typing of individuals is becoming an important assessment tool that allows customization of nutritional requirements to obtain the best possible outcomes from precision nutrition [15], as a function of different lifestyles and critical illness (such as myopathy, cardiomyopathy, and neuropathy) [16]. Metabolomics may directly assess the nutritional composition and authenticity of food, plant varieties, and crop cultivars, information which are indispensable to both consumers and food producers who take an interest in potential health benefits and nutritional value of foods seen as ‘nutraceuticals’ [17].

In the health field, many pathophysiological states include a metabolic component. A general rewiring of energy metabolism is a hallmark of aging [18,19], neurodegenerative diseases [19–21], and cancer [22,23]. Otto

Warburg reported the first evidence of an altered metabolic phenotype in cancer a century ago [24]. Recent evidence shows that metabolic rewiring occurs both as an indirect consequence of oncogenic mutations, as well as by direct mutation of genes encoding metabolic enzymes, such as the genes encoding the tricarboxylic acid cycle enzymes Fumarate Hydratase, Succinate Dehydrogenase, and Isocitrate Dehydrogenase. These events may lead to the accumulation of metabolites – referred to as *oncometabolites* – that can act as oncogenic signaling molecules [25]. Interestingly, opposite transcriptional modulation of the genes encoding Isocitrate Dehydrogenase contributes to cancer and neurodegeneration [26].

A physiological, system-level analysis of metabolism – obtained through high-resolution respirometry (Oxygraph 2k, Oroboros Instruments) [27] and extracellular flux analysis (Seahorse eXtracellular Flux (XF) analyzer,

Agilent) – allows to characterize the overall metabolic phenotype of cells (cultured as adherent monolayers (2D) or spheroids (3D) in a multi-well plate format) and tissues. Seahorse technology measures simultaneously mitochondrial respiration and glycolysis and their dependence on drug and nutritional stress, putting in context data obtained by metabolomics, drug sensitivity, or labeling experiments [28–31].

As witnessed by the ever-increasing application in clinical cancer research [22,32,33], the use of metabolomics in personalized medicine aims to identify the most effective treatment in patients based on their response towards particular drugs [34] and guide the development of more effective drugs by providing a better understanding of the system-wide effectiveness they have *in vivo*.

Metabolic modeling meets artificial intelligence

Computational tools are needed to contextualize experimental observations into a systems-level understanding of metabolic alterations. By way of example, information on enzyme concentrations and metabolomics must be translated into information on metabolic flux distributions, whose experimental determination may not always be feasible, especially in a clinical setting.

The application of Artificial Intelligence to this problem has so far remained sporadic, mainly due to the large number of data required for efficiently training machine learning algorithms, on the one side, and to the limited access to public metabolic data on the other side [35]. Existing studies mainly attempt to predict metabolomes from proteomic [36] or multi-series omic data [37] or the metabolic flux of a small portion of a network, such as the upper part of glycolysis [38]. Moreover, machine learning algorithms are characterized by the well-known black box problem, which makes it difficult to know how and why they work [39].

Constraint-based metabolic network modeling has been more successful in providing a mechanistic understanding of metabolism, providing predictions of changes of fluxes as a function of nutrient supply. Genome-Wide Metabolic Models (GEMs, [40]) include thousands of reactions and describe genotype-to-phenotype association mechanistically, through Gene-Protein-Reaction (GPR) associations. Core models include a reduced number of reactions and may help in the identification of the design principles governing each metabolic pattern rewiring. Constraint-based simulation of a core model describing glucose and glutamine conversion into biomass [41] showed that when available oxygen is not sufficient to fully oxidize available glucose and glutamine carbons, a situation often observed even in normoxia, reductive carboxylation of glutamine, and conversion of glucose and glutamine to lactate, confer an advantage for biomass production. GEMs (and core


models) provide cellular context for omic data analysis, enabling to go beyond simple statistical correlations [42,43], or standard machine learning methods [44,45]. In the more typical and straightforward case, metabolomic data of spent culture media are used to derive constraints on extracellular fluxes [46].

The steady-state assumption and constraints on extracellular fluxes do not result in a unique steady-state flux distribution. For this reason, many algorithms have been proposed for the integration of other high-throughput data to further reduce the solution space of feasible flux phenotypes, with particular regard to transcriptomic data. These algorithms may map transcriptomic data to topological information in GEMs to enrich for metabolites [47] or metabolic reactions [48]. Other algorithms extract a subnetwork of the GEM that corresponds uniquely to active reactions in the context of interest or predict metabolic flux distributions. This objective is achieved by incorporating data into constraint-based simulations, either providing constraints on the values of admitted fluxes (e.g. scFBA [49], eFlux [50]) or leading to the formulation of an objective function that seeks to minimize the distance between predicted flux distribution and data (e.g. *GIMME* [51], *tINIT* [52], *iMAT* [53]). Most of the latter algorithms have been reviewed and benchmarked in Refs. [54,55,56].

Metabolomic data are more tightly related to metabolism than transcriptomic data, but their integration is more challenging (Figure 2). Some methods ask the network to produce specific metabolites at the stage of context-specific network reconstruction or require demanding time-series data [57,58]. iReMet-Flux integrates metabolomic data in a metabolic model predicting fluxes in a way that complements methods based on radioactive tracer labeling [59]. More recent studies – reviewed in Ref. [58] – attempt to directly incorporate knowledge on relative changes (after a perturbation) in metabolite abundances as model constraints [57,58,60].

Approaches coupling metabolic modeling with artificial intelligence use the mechanistically linked information provided by context-specific models as the input of either supervised or unsupervised machine learning approaches, as reviewed in Refs. [61–63]. Unsupervised approaches typically aim at partitioning condition-specific metabolic networks or flux distributions, based on intra-cluster similarity and inter-cluster dissimilarity, and/or at reducing their dimensionality to essential components, retaining only features that are responsible for the variability in the data. A recent example uses principal component analysis on a thousand cancer genome-scale metabolic models [64]. The work shows that tumor metabolic networks differ more in the expression of specific enzyme-encoding genes than in the structure of the network itself. After training an algorithm with many examples of model-

Figure 2



Current Opinion in Biotechnology

Families of modeling and artificial intelligence approaches to systems metabolomics and explicative examples.

property pairs, supervised approaches more often aim to identify a function that correctly predicts a phenotypic property associated with any metabolic network or flux distribution. For instance, Shaked *et al.* [65] built a classifier that determines whether or not a drug causes side effects based on constraint-based simulations of the inactivation of the drug's targets. These studies typically also exploit feature selection algorithms to identify the set of features (genes, reactions, or pathways) that improve the accuracy of the predictor. In Ref. [62], the identification of genes more relevant for segregating between cancer and healthy models leads to the identification of new drug targets. In Ref. [66**], the simulated metabolic fluxes that mostly determine the level of the concentration of antibiotic needed to inhibit bacterial growth provided novel indication on pathways involved in antibiotic resistance.

Multi-omic and single-cell analysis of metabolism

New computational frameworks are being developed to exploit the increasing availability of multi-omic data. They can be used, for instance, to better identify a metabolic signature capable of predicting patient survival integrating metabolomics, lipidomics, and transcriptomics [67], to improve patient stratification via multi-view clustering algorithms (such as Ref. [68], as reviewed in Ref. [69]), to discover biological pathways with correlated profiles across multiple complex data sets [70].

GEMs offer a knowledge-based opportunity to integrate the different sources to provide a unified vision of the systems under study. For example, [60*] incorporates the determination of the relative levels of both metabolites and transcripts. A recent study [71**] combines multi-omic data integration with metabolic network and machine learning to recapitulate the regulation of breast cancer cell metabolism.


A major challenge is now posed by metabolic heterogeneity at the intra-tissue level. Many tissue metabolic functions – and dysfunctions – rely on interactions between cell types. For example, the metabolic interplay that occurs among cancer and stromal cells contributes to cancer development and resistance to treatment. Thus, multicellular, constraint-based models are being proposed that integrate the metabolic activities of multiple cell types, such as Refs. [72,73] and other papers reviewed in Ref. [74].

Single-cell omics allow phenotypic characterization of cells at high resolution. Single-cell metabolomics poses significant challenges because of the low analyte abundances and limited sample volumes [75]. With its high spatial resolution, imaging mass spectrometry, can map and quantify a wide range of unlabeled small molecules [76**,77,78] review some applications in the field of cancer and neurodegeneration, respectively.

High Content Analysis (HCA, or cell-omics) correlates high-resolution spatial information with quantitative parameters, including the level of specific metabolites, or the expression and activity of specific metabolic enzymes or their regulators, using *in vitro* biochemical assays [79]. Many HCA studies of metabolism use specific fluorescent probes on live cellular models (cell lines or primary cells, cultured in 2D or 3D, tissue samples, and organoids). Potentiometric and non-potentiometric mitochondrion-selective probes allow studying parameters strictly related to the mitochondria function (fission, fusion, fragmentation, membrane potential) [80]. Probes measuring mitochondrial or cytoplasmic reactive oxygen species (ROS) [81] and genetically encoded ratiometric fluorescent sensors specific for pyridine nucleotides, such as NADH, NADPH or thiols [82,83] allow measuring redox homeostasis. Of particular interest is the possibility to study the redox state of live cells by taking advantage of the autofluorescence of specific metabolites, such as nicotinamide adenine dinucleotide (phosphate) (NAD(P)H), flavin adenine dinucleotide (FAD) that allow for label-free quantification of metabolic activity of individual cells over time and in response to various stimuli [84,85]. The multiparametric nature of HCA allows correlating the cellular metabolic status or the response to specific metabolic perturbation in real-time and at the single-cell level to many important phenotypic traits, including cell proliferation and apoptosis, autophagy, cell migration or invasion.

The collection and analysis of single-cell RNA sequencing (scRNA-seq) data have significantly advanced and increased our knowledge of gene expression heterogeneity [86], but little application to metabolism have so far been reported. Single-cell Flux Balance Analysis [49*] allows translating single-cell RNA profiles into single-cell fluxes. The exchange of metabolites among cells allows the identification of possible inter-cellular metabolic interactions and to cluster cells according to the growth rate, a parameter strongly related to the tumor aggressiveness. This kind of analysis does not directly provide information on the spatial distribution of cells. FBCA (Flux Balance Analysis with Cellular Automata), couples biomass accumulation (simulated via Flux Balance Analysis of metabolic networks), with the simulation of spatial dynamics (via Cellular Potts Models) of cell populations that communicate through metabolite secretion [87]. Integration of FBCA (extended in 3D, compared to actual 2D analysis) and scFBA may provide the foundation for determining spatially resolved single-cell fluxes of heterogeneous cell populations in clinical and pre-clinical models. Using a similar approach that combines metabolic modeling with cellular automata, Shan *et al.*, provided a multi-scale model that stresses the importance of taking into account spatial and temporal evolution of the tumor microenvironment for a complete understanding of different metabolic scenarios such as the Warburg and reverse Warburg effects or glutamine addiction [88].

Figure 3



A flow chart for a systems metabolomics approach applied to personalized therapy of multifactorial diseases.

Conclusions and perspectives

Changes in the levels of metabolites and their cognate fluxes are sensitive readouts of the response of biological systems to genetic and/or environmental perturbations. These changes result from the complex, non-linear interaction of metabolic, signaling, and regulatory pathways. A broad spectrum of techniques allow accurate and sensitive measurement of metabolites and metabolic fluxes. Cytological, high content, and physiological techniques allow the overall characterization of the physiological state of cells and tissues as well as their dependence on specific nutrients. Constraint-based metabolic models provide a framework for the integration of high-throughput data, such as population and single-cell transcriptomic data, as well as multi-omic data [89].

Systems metabolomics combines these different experimental and computational approaches aiming to unravel the design principles of metabolic regulation. In molecular oncology, systems metabolomics studies the interconnection of metabolism with physio-pathologically relevant properties, such as proliferation [3,41,52] or metastatic dissemination [90,91^{••}], with the final aim to provide the rational basis for the development of individually tailored precision oncology therapeutic strategies. It can contribute to the development of pre-clinical pipelines that incorporate information derived by systematic perturbation analysis of experimental models of cancer patients — including patient-derived cell lines, spheroids, organoids, and organs-on-chip, and xenotransplants (PDXs). Since integrated analyses are costly, time-consuming, and often unfeasible in a clinical setting, a primary goal of systems metabolomics is to derive appropriate proxies to be used in the design of combinatorial drug treatments as well as in the therapeutic follow-up (Figure 3).

By similar reasoning, in nutrition and wellness, a personalized systems metabolomics approach would provide a complete picture of the functioning of the person's metabolism, allowing a prediction of the effects that the administration of particular diets would have on the organism. The identification of the design principles connecting nutrient utilization to metabolic functioning and the organism's ability to cope with environmental insults would lead to the rational formulation of appropriate alimentary regimens tailored for the wellness of each individual according to the various phases of a person's life and her/his 'lifestyle'. Such a rational approach can actively contribute to preventing disease development, better support people under pharmacological treatments, entailing an enormous advance in terms of both the prevention of diseases and an improvement in the quality of life.

Author contributions

Lilia Alberghina discussed the review idea and revised the paper.

Chiara Damiani, Daniela Gaglio and Elena Sacco wrote the paper, conceived, and prepared the figures.

Marco Vanoni conceived the review idea, discussed the images, wrote and revised the paper.

Conflict of interest statement

Nothing declared.

Acknowledgements

The institutional financial support to SYSBIO.ISBE.IT within the Italian Roadmap for ESFRI Research Infrastructures, the FLAG-ERA grant ITFoC and H2020 grants EpiPredict n. 642691 and Amplitude n. 871277 to LA and MV is gratefully acknowledged. Financial support from the Italian Ministry of University and Research (MIUR) through grant 'Dipartimenti di Eccellenza 2017' to University of Milano Bicocca is also greatly acknowledged.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
 - of outstanding interest
1. Zamboni N, Saghatelian A, Patti GJ: **Defining the metabolome: size, flux, and regulation.** *Mol Cell* 2015, **58**:699-706.
 2. Cordes T, Metallo CM: **Quantifying intermediary metabolism and lipogenesis in cultured mammalian cells using stable isotope tracing and mass spectrometry.** *Methods Mol Biol* 2019, **1978**:219-241.
 3. Nielsen J: **Systems biology of metabolism: a driver for developing personalized and precision medicine.** *Cell Metab* 2017, **25**:572-579.
 4. Liu X, Locasale JW: **Metabolomics: a primer.** *Trends Biochem Sci* 2017, **42**:274-284.
 5. Jang C, Chen L, Rabinowitz JD: **Metabolomics and isotope tracing.** *Cell* 2018, **173**:822-837.
 6. Liu X, Locasale JW: **Metabolomics reveals intratumor heterogeneity - implications for precision medicine.** *EBioMedicine* 2017, **19**:4-5.
 7. Pinu FR, Beale DJ, Paten AM, Kouremenos K, Swarup S, Schirra HJ, Wishart D: **Systems biology and multi-omics integration: viewpoints from the metabolomics research community.** *Metabolites* 2019, **9**.
 8. Pinu FR, Goldansaz SA, Jaine J: **Translational metabolomics: current challenges and future opportunities.** *Metabolites* 2019, **9**.
- The authors report on the integrated use of multiple omic techniques, reviewing methods, software tools, and databases in a format intended to serve as a guide to the design and analysis of multi-omics studies.
9. Pinu FR, Villas-Boas SG, Martin D: **Pre-fermentative supplementation of fatty acids alters the metabolic activity of wine yeasts.** *Food Res Int* 2019, **121**:835-844.
 10. Lee SY, Kim HU: **Systems strategies for developing industrial microbial strains.** *Nat Biotechnol* 2015, **33**:1061-1072.
 11. Choi KR, Kim WJ, Lee SY: **Metabolomics for industrial fermentation.** *Bioprocess Biosyst Eng* 2018, **41**:1073-1077.
 12. Guasch-Ferré M, Bhupathiraju SN, Hu FB: **Use of metabolomics in improving assessment of dietary intake.** *Clin Chem* 2018, **64**:82-98.
 13. Sakaguchi CA, Nieman DC, Signini EF, Abreu RM, Catai AM: **Metabolomics-based studies assessing exercise-induced alterations of the human metabolome: a systematic review.** *Metabolites* 2019, **9**.

14. Jin Q, Black A, Kales SN, Vatter D, Ruiz-Canela M, Sotos-Prieto M: **Metabolomics and microbiomes as potential tools to evaluate the effects of the Mediterranean diet.** *Nutrients* 2019, **11**.
15. Tebani A, Bekri S: **Paving the way to precision nutrition through metabolomics.** *Front Nutr* 2019, **6**:41.
16. Christopher KB: **Nutritional metabolomics in critical illness.** *Curr Opin Clin Nutr Metab Care* 2018, **21**:121-125.
17. Erban A, Fehrle I, Martinez-Seidel F, Brigante F, Más AL, Baroni V, Wunderlin D, Kopka J: **Discovery of food identity markers by metabolomics and machine learning technology.** *Sci Rep* 2019, **9**:9697.
18. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G: **The hallmarks of aging.** *Cell* 2013, **153**:1194-1217.
19. Qi G, Mi Y, Yin F: **Cellular specificity and inter-cellular coordination in the brain bioenergetic system: implications for aging and neurodegeneration.** *Front Physiol* 2019, **10**:1531.
20. Trošt M, Perovnik M, Pirtošek Z: **Correlations of neuropsychological and metabolic brain changes in Parkinson's disease and other α -synucleinopathies.** *Front Neurol* 2019, **10**:1204.
21. Antony PM, Diederich NJ, Krüger R, Balling R: **The hallmarks of Parkinson's disease.** *FEBS J* 2013, **280**:5981-5993.
22. Kaushik AK, DeBerardinis RJ: **Applications of metabolomics to study cancer metabolism.** *Biochim Biophys Acta Rev Cancer* 2018, **1870**:2-14.
23. Zhu J, Thompson CB: **Metabolic regulation of cell growth and proliferation.** *Nat Rev Mol Cell Biol* 2019, **20**:436-450.
24. Warburg O, Wind F, Negelein E: **The metabolism of tumors in the body.** *J Gen Physiol* 1927, **8**:519-530.
25. Sciacovelli M, Frezza C: **Oncometabolites: unconventional triggers of oncogenic signalling cascades.** *Free Radic Biol Med* 2016, **100**:175-181.
26. Tommasini-Ghelfi S, Murnan K, Kouri FM, Mahajan AS, May JL, Stegh AH: **Cancer-associated mutation and beyond: the emerging biology of isocitrate dehydrogenases in human disease.** *Sci Adv* 2019, **5**:eaaw4543.
27. Makrecka-Kuka M, Krumschnabel G, Gnaiger E: **High-resolution respirometry for simultaneous measurement of oxygen and hydrogen peroxide fluxes in permeabilized cells, tissue homogenate and isolated mitochondria.** *Biomolecules* 2015, **5**:1319-1338.
28. Bacci M, Lorito N, Ippolito L, Ramazzotti M, Luti S, Romagnoli S, Parri M, Bianchini F, Cappellesso F, Virga F *et al.*: **Reprogramming of amino acid transporters to support aspartate and glutamate dependency sustains endocrine resistance in breast cancer.** *Cell Rep* 2019, **28**:104-118.e108.
29. Denise C, Paoli P, Calvani M, Taddei ML, Giannoni E, Kopetz S, Kazmi SM, Pia MM, Pettazoni P, Sacco E *et al.*: **5-Fluorouracil resistant colon cancer cells are addicted to OXPPOS to survive and enhance stem-like traits.** *Oncotarget* 2015, **6**:41706-41721.
30. Russell S, Wojtkowiak J, Neilson A, Gillies RJ: **Metabolic profiling of healthy and cancerous tissues in 2D and 3D.** *Sci Rep* 2017, **7**:15285.
31. Palorini R, Votta G, Pirola Y, De Vitto H, De Palma S, Airoldi C, Vasso M, Ricciardiello F, Lombardi PP, Cirulli C *et al.*: **Protein kinase A activation promotes cancer cell resistance to glucose starvation and anoikis.** *PLoS Genet* 2016, **12**:e1005931.
32. Ortmayr K, Dubuis S, Zampieri M: **Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism.** *Nat Commun* 2019, **10**:1841.
33. Intlekofer AM, Finley LWS: **Metabolic signatures of cancer cells and stem cells.** *Nat Metab* 2019, **1**:177-188.
34. Chen R, Snyder M: **Promise of personalized omics to precision medicine.** *Wiley Interdiscip Rev Syst Biol Med* 2013, **5**:73-82.
35. Editorial: **Why the metabolism field risks missing out on the AI revolution.** *Nat Metab* 2019, **2**.
The editorial discusses some of the reasons that have so far hampered widespread and effective utilization of AI tools in metabolomics.
36. Zelezniak A, Vowinckel J, Capuano F, Messner CB, Demichev V, Polowsky N, Müllereder M, Kamrad S, Klaus B, Keller MA *et al.*: **Machine learning predicts the yeast metabolome from the quantitative proteome of kinase knockouts.** *Cell Syst* 2018, **7**:269-283.e266.
37. Costello Z, Martin HG: **A machine learning approach to predict metabolic pathway dynamics from time-series multiomics data.** *NPJ Syst Biol Appl* 2018, **4**:19.
38. Ajjoli Nagaraja A, Fontaine N, Delsaut M, Charton P, Damour C, Offmann B, Grondin-Perez B, Cadet F: **Flux prediction using artificial neural network (ANN) for the upper part of glycolysis.** *PLoS One* 2019, **14**:e0216178.
39. Castelvechi D: **Can we open the black box of AI?** *Nature* 2016, **538**:20-23.
40. Brunk E, Sahoo S, Zielinski DC, Altunkaya A, Dräger A, Mih N, Gatto F, Nilsson A, Preciat Gonzalez GA, Aurich MK *et al.*: **Recon3D enables a three-dimensional view of gene variation in human metabolism.** *Nat Biotechnol* 2018, **36**:272-281.
41. Damiani C, Colombo R, Gaglio D, Mastroianni F, Pescini D, Westerhoff HV, Mauri G, Vanoni M, Alberghina L: **A metabolic core model elucidates how enhanced utilization of glucose and glutamine, with enhanced glutamine-dependent lactate production, promotes cancer cell growth: the WarburQ effect.** *PLoS Comput Biol* 2017, **13**:e1005758.
42. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK: **Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.** *Science* 2012, **336**:1040-1044.
43. Siddiqui JK, Baskin E, Liu M, Cantemir-Stone CZ, Zhang B, Bonneville R, McElroy JP, Coombes KR, Mathé EA: **IntLIM: integration using linear models of metabolomics and gene expression data.** *BMC Bioinformatics* 2018, **19**:81.
44. Diener C, Resendis-Antonio O: **Personalized prediction of proliferation rates and metabolic liabilities in cancer biopsies.** *Front Physiol* 2016, **7**:644.
45. Inglese P, McKenzie JS, Mroz A, Kinross J, Veselkov K, Holmes E, Takats Z, Nicholson JK, Glen RC: **Deep learning and 3D-DESI imaging reveal the hidden metabolic heterogeneity of cancer.** *Chem Sci* 2017, **8**:3500-3511.
46. Aurich MK, Fleming RMT, Thiele I: **A systems approach reveals distinct metabolic strategies among the NCI-60 cancer cell lines.** *PLoS Comput Biol* 2017, **13**:e1005698.
47. Patil KR, Nielsen J: **Uncovering transcriptional regulation of metabolism by using metabolic network topology.** *Proc Natl Acad Sci U S A* 2005, **102**:2685-2689.
48. Graudenzi A, Maspero D, Di Filippo M, Gnugnoli M, Isella C, Mauri G, Medico E, Antoniotti M, Damiani C: **Integration of transcriptomic data and metabolic networks in cancer samples reveals highly significant prognostic power.** *J Biomed Inform* 2018, **87**:37-49.
49. Damiani C, Maspero D, Di Filippo M, Colombo R, Pescini D, Graudenzi A, Westerhoff HV, Alberghina L, Vanoni M, Mauri G: **Integration of single-cell RNA-seq data into population models to characterize cancer metabolism.** *PLoS Comput Biol* 2019, **15**:e1006733.
The first approach to integrate data from single-cell transcriptomics and bulk metabolomics into a multi-scale stoichiometric model to deliver metabolic fluxes at the single-cell level.
50. Colijn C, Brandes A, Zucker J, Lun DS, Weiner B, Farhat MR, Cheng TY, Moody DB, Murray M, Galagan JE: **Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production.** *PLoS Comput Biol* 2009, **5**:e1000489.
51. Becker SA, Palsson BO: **Context-specific metabolic networks are consistent with experiments.** *PLoS Comput Biol* 2008, **4**:e1000082.

52. Agren R, Bordel S, Mardinoglu A, Pornputtpong N, Nookaew I, Nielsen J: **Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT**. *PLoS Comput Biol* 2012, **8**:e1002518.
53. Zur H, Ruppig E, Shlomi T: **iMAT: an integrative metabolic analysis tool**. *Bioinformatics* 2010, **26**:3140-3142.
54. Jamialahmadi O, Hashemi-Najafabadi S, Motamedian E, Romeo S, Bagheri F: **A benchmark-driven approach to reconstruct metabolic networks for studying cancer metabolism**. *PLoS Comput Biol* 2019, **15**:e1006936.
- While extensively benchmarking current context-specific model reconstruction methods from transcriptomics, the authors demonstrate that model predictions significantly improve when setting extracellular fluxes using experimentally derived constraints.
55. Opdam S, Richelle A, Kellman B, Li S, Zielinski DC, Lewis NE: **A systematic evaluation of methods for tailoring genome-scale metabolic models**. *Cell Syst* 2017, **4**:318-329.e316.
- While evaluating the capability to predict gene essentiality of current context-specific model reconstruction methods, the authors show that the choice of gene expression thresholds influences prediction more than the choice of the integration method.
56. Machado D, Herrgård M: **Systematic evaluation of methods for integration of transcriptomic data into constraint-based models of metabolism**. *PLoS Comput Biol* 2014, **10**:e1003580.
57. Kleessen S, Irgang S, Klie S, Giavalisco P, Nikoloski Z: **Integration of transcriptomics and metabolomics data specifies the metabolic response of *Chlamydomonas* to rapamycin treatment**. *Plant J* 2015, **81**:822-835.
58. Töpfer N, Kleessen S, Nikoloski Z: **Integration of metabolomics data into metabolic networks**. *Front Plant Sci* 2015, **6**:49.
59. Sajitz-Hermstein M, Töpfer N, Kleessen S, Fernie AR, Nikoloski Z: **iReMet-flux: constraint-based approach for integrating relative metabolite levels into a stoichiometric metabolic models**. *Bioinformatics* 2016, **32**:i755-i762.
60. Pandey V, Hadadi N, Hatzimanikatis V: **Enhanced flux prediction by integrating relative expression and relative metabolite abundance into thermodynamically consistent metabolic models**. *PLoS Comput Biol* 2019, **15**:e1007036.
- The author applied the proposed method to a GEM of *E. coli* to estimate the central carbon metabolism fluxes. The integration of both metabolomics and transcriptomics improve predictions.
61. Pacheco MP, Bintener T, Sauter T: **Towards the network-based prediction of repurposed drugs using patient-specific metabolic models**. *EBioMedicine* 2019, **43**:26-27.
62. Pacheco MP, Bintener T, Ternes D, Kulms D, Haan S, Letellier E, Sauter T: **Identifying and targeting cancer-specific metabolism with network-based drug target prediction**. *EBioMedicine* 2019, **43**:98-106.
63. Zampieri G, Vijayakumar S, Yaneske E, Angione C: **Machine and deep learning meet genome-scale metabolic modeling**. *PLoS Comput Biol* 2019, **15**:e1007084.
64. Gatto F, Ferreira R, Nielsen J: **Pan-cancer analysis of the metabolic reaction network**. *Metab Eng* 2019, **57**:51-62.
65. Shaked I, Oberhardt MA, Atlas N, Sharan R, Ruppig E: **Metabolic network prediction of drug side effects**. *Cell Syst* 2016, **2**:209-213.
66. Yang JH, Wright SN, Hamblin M, McCloskey D, Alcantar MA, Schrübbers L, Lopatkin AJ, Satish S, Nili A, Palsson BO *et al.*: **A white-box machine learning approach for revealing antibiotic mechanisms of action**. *Cell* 2019, **177**:1649-1661.e1649.
- By using FBA results of *E. coli* GEM model for different simulated growth media and the experimentally measured lethality of three antibiotics for each media as an input of machine learning algorithms, the authors identify novel metabolic pathways involved in antibiotic resistance.
67. Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, Putluri V, Ravi SS, Robertson MJ, Piyarathna DWB *et al.*: **Multi-omics integration analysis robustly predicts high-grade patient survival and identifies CPT1B effect on fatty acid metabolism in bladder cancer**. *Clin Cancer Res* 2019, **25**:3689-3701.
68. Ramazzotti D, Lal A, Wang B, Batzoglu S, Sidow A: **Multi-omic tumor data reveal diversity of molecular mechanisms that correlate with survival**. *Nat Commun* 2018, **9**:4453.
69. Rappoport N, Shamir R: **Multi-omic and multi-view clustering algorithms: review and cancer benchmark**. *Nucleic Acids Res* 2018, **46**:10546-10562.
70. Meng C, Basunia A, Peters B, Gholami AM, Kuster B, Culhane AC: **MOGSA: integrative single sample gene-set analysis of multiple omics data**. *Mol Cell Proteomics* 2019, **18**:S153-S168.
71. Katzir R, Polat IH, Harel M, Katz S, Foguet C, Selivanov VA, Sabatier P, Cascante M, Geiger T, Ruppig E: **The landscape of tiered regulation of breast cancer cell metabolism**. *Sci Rep* 2019, **9**:17760.
- The authors integrate transcriptomics, proteomics, phosphoproteomics measurements, as well as some fluxes estimated with metabolic flux analysis and the others with context-specific GEMS, of a breast cancer cell line, grown under three different conditions.
72. Capuani F, De Martino D, Marinari E, De Martino A: **Quantitative constraint-based computational model of tumor-to-stroma coupling via lactate shuttle**. *Sci Rep* 2015, **5**:11880.
73. Lewis NE, Schramm G, Bordbar A, Schellenberger J, Andersen MP, Cheng JK, Patel N, Yee A, Lewis RA, Eils R *et al.*: **Large-scale in silico modeling of metabolic interactions between cell types in the human brain**. *Nat Biotechnol* 2010, **28**:1279-1285.
74. Martins Conde PoR, Sauter T, Pfau T: **Constraint based modeling going multicellular**. *Front Mol Biosci* 2016, **3**:3.
75. Duncan KD, Fyrestam J, Lanekoff I: **Advances in mass spectrometry based single-cell metabolomics**. *Analyst* 2019, **144**:782-793.
76. Sun C, Li T, Song X, Huang L, Zang Q, Xu J, Bi N, Jiao G, Hao Y, Chen Y *et al.*: **Spatially resolved metabolomics to discover tumor-associated metabolic alterations**. *Proc Natl Acad Sci U S A* 2019, **116**:52-57.
- The authors propose a spatially resolved metabolomics approach to discover tumor-associated metabolites and metabolic enzymes directly in their native state, providing insights into the understanding of cancer metabolic reprogramming.
77. Goodwin RJ, Bunch J, McGinnity DF: **Mass spectrometry imaging in oncology drug discovery**. *Adv Cancer Res* 2017, **134**:133-171.
78. Chen K, Baluya D, Tosun M, Li F, Maletic-Savatic M: **Imaging mass spectrometry: a new tool to assess molecular underpinnings of neurodegeneration**. *Metabolites* 2019, **9**.
79. Mattiazzi Usaj M, Styles EB, Verster AJ, Friesen H, Boone C, Andrews BJ: **High-content screening for quantitative cell biology**. *Trends Cell Biol* 2016, **26**:598-611.
80. Leonard AP, Cameron RB, Speiser JL, Wolf BJ, Peterson YK, Schnellmann RG, Beeson CC, Rohrer B: **Quantitative analysis of mitochondrial morphology and membrane potential in living cells using high-content imaging, machine learning, and morphological binning**. *Biochim Biophys Acta* 2015, **1853**:348-360.
81. Sieprath T, Corne T, Robijns J, Koopman WJH, De Vos WH: **Cellular redox profiling using high-content microscopy**. *J Vis Exp* 2017, **123**:e55449.
82. Tao R, Zhao Y, Chu H, Wang A, Zhu J, Chen X, Zou Y, Shi M, Liu R, Su N *et al.*: **Genetically encoded fluorescent sensors reveal dynamic regulation of NADPH metabolism**. *Nat Methods* 2017, **14**:720-728.
83. Zou Y, Wang A, Shi M, Chen X, Liu R, Li T, Zhang C, Zhang Z, Zhu L, Ju Z *et al.*: **Analysis of redox landscapes and dynamics in living cells and in vivo using genetically encoded fluorescent sensors**. *Nat Protoc* 2018, **13**:2362-2386.
84. Schaefer PM, Kalinina S, Rueck A, von Arnim CAF, von Einem B: **NADH autofluorescence-a marker on its way to boost bioenergetic research**. *Cytometry A* 2019, **95**:34-46.
85. Willingham TB, Zhang Y, Andreoni A, Knutson JR, Lee DY, Glancy B: **MitoRACE: evaluating mitochondrial function in vivo**

- and in single cells with subcellular resolution using multiphoton NADH autofluorescence. *J Physiol* 2019, **597**:5411-5428.
86. Kulkarni A, Anderson AG, Merullo DP, Konopka G: **Beyond bulk: a review of single cell transcriptomics methodologies and applications.** *Curr Opin Biotechnol* 2019, **58**:129-136.
87. Maspero D, Damiani C, Antoniotti M, Graudenzi A, Di Filippo M, Vanoni M, Caravagna G, Colombo R, Ramazzotti D, Pescini D: **The influence of nutrients diffusion on a metabolism-driven model of a multi-cellular system.** *Fundam Inform* 2020, **171**:17.
88. Shan M, Dai D, Vudem A, Varner JD, Stroock AD: **Multi-scale computational study of the Warburg effect, reverse Warburg effect and glutamine addiction in solid tumors.** *PLoS Comput Biol* 2018, **14**:e1006584.
89. Di Filippo M, Damiani C, Vanoni M, Maspero D, Mauri G, Alberghina L, Pescini D: **Single-cell digital twins for cancer preclinical investigation.** *Methods Mol Biol* 2020, **2088**:331-343.
90. Yizhak K, Le Dévédec SE, Rogkoti VM, Baenke F, de Boer VC, Frezza C, Schulze A, van de Water B, Ruppin E: **A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration.** *Mol Syst Biol* 2014, **10**:744.
91. Fendt SM: **Metabolic vulnerabilities of metastasizing cancer cells.** *BMC Biol* 2019, **17**:54.
The author reviews the distinct, targetable metabolism of metastasizing cancer cells and discusses potential therapeutic opportunities provided by their metabolic vulnerabilities.